Study for breast cancer that has spread to other parts of the body.

Trial ID:
IRB-22-8006
Mohammed Ali Jaloudi, MD
This study is evaluating an investigational combination treatment compared to current approved anti-cancer medications for ER-positive/HER2-negative breast cancer that has spread to parts of the body beyond the breast.
There is no placebo in this clinical study. Everyone receives treatment with a combination of oral breast cancer medications taken once per day for each 28Day cycle. Study visits include health checks, tests, and questionnaires. All study visits will be scheduled at Scripps Clinic Torrey Pines or Scripps Clinic Encinitas.

Inclusion Criteria

Patients must:

  • Be male or female age 18Yrs or older; AND

    Have estrogen receptor (ER)-positive/human epidermal growth factor (HER2)-negative cancer; AND

    Have been previously treated for breast cancer; AND

    Have cancer that has returned or worsened; AND

    Have cancer that has spread in a way that cannot be treated with surgery.

Exclusion Criteria

Patients must not:

  • Have significant bowel disease, chronic diarrhea or major upper gastrointestinal surgery potentially affecting the absorption of oral medications;

    Have significant lung disease requiring oxygen therapy;

    Be pregnant or breastfeeding, or planning to become pregnant during the study or within 8 weeks after the final dose of oral medication.

Additional Info

This is an open-label study which means you will know which group you are in. There is no placebo in this clinical study. Everyone receives treatment with a combination of two breast cancer medications.

Giredestrant is an investigational drug designed to block the sex hormone called estrogen that contributes to the cancer's growth and progression.


Search NCT05306340 at https://clinicaltrials.gov website for more information

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org